A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Exclusion Criteria

• •NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
• •Mixed NSCLC and small cell lung cancer histology
• •Any prior therapy for lung cancer
• •Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
• •Non-squamous NSCLC histology with activating ALK and EGFR mutation
• •Pregnant or lactating women
• •History of autoimmune disease
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or evidence of active of active pneumonitis on screening chest Computed Tomography (CT) scan
• •Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
• •Severe infection within 4 weeks prior to randomization
• •Significant history of cardiovascular disease